In 2018, the Foundation for the National Institutes of Health (FNIH) will present the FNIH Trailblazer Prize for Clinician-Scientists (Trailblazer Prize), which recognizes the outstanding contributions of early career clinician-scientists whose work has the potential to or has led to innovations in patient care. This $10,000 honorarium and prize celebrates the achievements of medical doctors… [Read More]
I read with interest the Diagnostic View (TR, April), which, according to the authors, represented a case of rhupus, an overlap syndrome of RA and SLE. I challenge this view. My arguments: In the case of erosive RA, typically erosive changes are seen at MTP joints other than MTP1 (e.g., MTP5). In addition, the erosive… [Read More]
I’m writing in regard to the article, “Fever of Unknown Origin” (TR, March 2016), by Charles Radis, DO. In regard to the non-caseating granulomas, there was no mention of epithelioid or giant cells. In addition, it was mainly [complement] C4 in the center of the granulomas, which is often found in sarcoidosis. Moreover, whether these… [Read More]
San Francisco, Nov. 6–11, 2015 The 2015 ACR/ARHP Annual Meeting in San Francisco was the most well attended in the College’s history. With the poster hall, exhibit hall, concurrent scheduling of multiple tracks and hundreds of scientific sessions presented during the event, the odds are good that even attendees missed a lot of what they… [Read More]
RA vs. Lyme I am writing to comment on your interesting and useful article that appeared on the front page of the August issue of The Rheumatologist, “RA vs. Lyme,” by Charles Radis, DO. Arriving at a definite diagnosis of active RA early on is often not an easy task. The author of this article… [Read More]
ROME, Italy—The European League Against Rheumatism (EULAR) annual congress (EULAR 2015) was a much-anticipated event, with more than 14,000 delegates attending from far and wide. The Health Professional Standing Committee was particularly delighted to have planned a program that provided the latest in research terms but also an eclectic mix of valuable topics for health… [Read More]
Dr. Simon Helfgott’s essay, “Barking at the Moon,” in the July 2015 issue of The Rheumatologist, about the unintended consequences of EHRs (electronic health records) prompted me to share my experience regarding the newly recognized KeMo disease. Keyboarding and mouse-clicking (KeMo) activity now consumes about 50% of the medical clinician’s day, as the modern EHRs… [Read More]
I found your recent article, “To Terminate or Not to Terminate?” (The Rheumatologist, April 2015), very relevant to my practice. The hospital system I practice in, Summa Health, Akron, Ohio, has two rheumatology groups with active hospital privileges. My partner and I are both part-time female rheumatologists who work for a hospital group, Summa Physicians… [Read More]
Glucocorticoids: The Debate Continues Déjà vu … In past decades, rheumatologists have seen, heard, practiced and taught much of what has been argued in the “ongoing debate” on the use of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA).1 It is heartening to note that eminent professors have stuck to their premise all these… [Read More]